Fei Wu

Dr. Fei Wu


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2021 in AAPS PharmSciTech
Verified
Journal Article
Closed access
PDF file
YLYu Luo
Yu Luo
YHYanlong Hong
Yanlong Hong
LSLan Shen
Lan Shen
FWFei Wu
Fei Wu
XLXiao Lin
Xiao Lin

1 January 2018 in Drug Delivery
Verified
Journal Article
Open access
XZXiao Zheng
Xiao Zheng
FWFei Wu
Fei Wu
XLXiao Lin
Xiao Lin
LSLan Shen
Lan Shen
YFYi Feng
Yi Feng
The bioactive alkaloids (e.g. vincristine, hydroxycamptothecin, ligustrazine, and so on) from traditional Chinese medicine (TCM) have exerted potent efficacies (e.g. anti-tumor, anti-inflammation, immunosuppression, etc.). However, a series of undesirable physicochemical properties (like low solubility and weak stability) and baneful pharmacokinetic (PK) profiles (e.g. low bioavailability, short half time, rapid clearance, etc.) have severely restricted their applications in clinic. In addition, some side effects (like cumulative toxicities caused by high-frequency administration and their own toxicities) have recently been reported and also confined their clinical uses. Therefore, developments in drug delivery of such alkaloids are of significance in improving their drug-like properties and, thus, treatment efficiencies in clinic. Strategies, including (i) specific delivery via liposomes; (ii) sustained delivery via nanoparticles, gels, and emulsions; and (iii) transdermal delivery via ethosomes, solid lipid nanoparticles, and penetrating enhancers, have been reported to improve the pharmacokinetic and physicochemical characters of problematic TCM alkaloids, decline their adverse effects, and thus, boost their curative efficacies. In this review, the recent reports in this field were comprehensively summarized with the aim of providing an informative reference for relevant readers.

12 September 2018 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
XZXiao Zheng
Xiao Zheng
FWFei Wu
Fei Wu
YHYanlong Hong
Yanlong Hong
LSLan Shen
Lan Shen
XLXiao Lin
Xiao Lin
YFYi Feng
Yi Feng
A variety of pharmacologically active substances, including chemotherapeutic drugs and the substances from traditional Chinese medicine (TCM), always exhibit potent bioactivities after oral administration. However, their unpleasant taste (such as bitterness) and/or odor always decrease patient compliance and thus compromise their curative efficacies in clinical application. Therefore, the developments of taste-masking techniques are of great significance in improving their organoleptic properties. However, though a variety of taste-masking techniques have been successfully used to mask the unpalatable taste of chemotherapeutic drugs, their suitability for TCM substances is relatively limited. This is mainly due to the fact that the bitter ingredients existing in multicomponent TCM systems (i.e., effective fractions, single Chinese herbs, and compound preparations) are always unclear, and thus, there is lack of tailor-made taste-masking techniques to be utilized to conceal their unpleasant taste. The relevant studies are also relatively limited. As a whole, three types of taste-masking techniques are generally applied to TCM, including (i) functional masking via sweeteners, bitter blockers, and taste modifiers; (ii) physical masking via polymer film-coating or lipid barrier systems; and (iii) biochemical masking via intermolecular interaction, β-cyclodextrin inclusion, or ion-exchange resins. This review fully summarizes the results reported in this field with the purpose of providing an informative reference for relevant readers.

5 April 2022 in AAPS PharmSciTech
Verified
Journal Article
Closed access
PDF file
TZTian-Yi Zhang
Tian-Yi Zhang
RDRuo-Fei Du
Ruo-Fei Du
YWYou-Jie Wang
You-Jie Wang
JHJia-Liang Hu
Jia-Liang Hu
FWFei Wu
Fei Wu
YFYi Feng
Yi Feng

1 November 2020 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
FWFei Wu
Fei Wu
HXHantao Xue
Hantao Xue
XLXiaocheng Li
Xiaocheng Li
WDWenbin Diao
Wenbin Diao
BJBin Jiang
Bin Jiang
GZGao Zhi-Qin
Gao Zhi-Qin
Hepatocellular carcinoma (HCC), a common malignancy in China and globally, is primarily treated through surgical resection and liver transplantation, with chemotherapy as a significant synergistic option. Adenine (Ade), a nucleobase, exhibits antitumor effects by blocking human hepatic carcinoma cells in S phase and inhibiting tumor cell proliferation. However, its use is limited owing to its low solubility, poor targeting ability, and nephrotoxicity. Therefore, liver-targeting drug delivery systems have attracted considerable attention for the treatment of HCC. In this study, we explored the liver-targeting efficacy and antitumor effect of adenine-loaded glycyrrhetinic acid-modified hyaluronic acid (Ade/GA-HA) nanoparticles in vitro and in vivo. The GA-HA nanoparticles possessed obvious targeting specificity toward liver cancer cells, which was mainly achieved by the specific binding of the GA ligand to the GA receptor that was highly expressed on the liver cell membrane. In vitro and in vivo results showed that Ade/GA-HA nanoparticles could inhibit liver cancer cell proliferation and migration, promote apoptosis, and significantly inhibit the growth of tumor tissues. Altogether, this study is the first to successfully demonstrate that the targeting activity and antitumor effect of Ade against HCC are enhanced by using GA-HA nanoparticles in vitro and in vivo.

27 October 2015 in RSC Advances
Verified
Journal Article
Closed access
PDF file
JLJinZhi Li
JinZhi Li
XLXiao Lin
Xiao Lin
FWFei Wu
Fei Wu
LSLan Shen
Lan Shen
YWYouJie Wang
YouJie Wang
YFYi Feng
Yi Feng
The central composite design-response surface methodology provided theoretical guidance for development of co-processed excipients based on calcium carbonate and HPMC.